Biomarkers

Neumora was founded in response to the lack of targeted, effective medicines for brain diseases and the high failure rates associated with neuroscience drug development. Including the investment from Amgen, the company has raised $500 million to date, with a Series A investment round led by ARCH Venture Partners.

PF is currently a general term. It can be caused by exposure to asbestos or silica dust, but is also seen in patients with autoimmune diseases such as systemic sclerosis or arthritis. It is known that genetic factors are important in risk of the condition. 

The success of this proof-of-principle study rests on the researchers’ discovery of a specific pattern of brain activity that indicates the onset of symptoms (a neural biomarker) in the patient, and their customizing the deep brain stimulation device to trigger a response selectively when it detects the pattern that constitutes the biomarker.

In a cohort of patients with advanced cervical cancer, researchers reported their new sequencing method detected 20-fold lower levels of HPV circulating tumor DNA.

Digital Insights to Tumor Biology is a complimentary, half-day virtual event dedicated to embracing not just the power of digital pathology but the value of partnerships and end-to-end workflows to better serve the scientific community. This complimentary digital event will address critical issues around biomarker development.

The comprehensive and integrated proteogenomic characterization is a valuable resource for the development of early detection strategies and identifies several promising new targets for pancreatic ductal adenocarcinoma treatment and early diagnosis.

The researchers identified differences in DNA methylation (DNAm) that accurately predicted different stages of liver fibrosis in as many as 94% of patients with non-alcoholic fatty liver disease (NAFLD), according to the study published in the journal Clinical Epigenetics.

Join us for this live Clinical OMICs webinar, sponsored by 10X Genomics, our distinguished presenters, Dr. Anna Lyubetskaya and Dr. Eugene Drokhlyansky, will explore the potential of spatial gene expression for various applications in clinical cohorts.

The Tabula Sapiens program aims to take the organs from the same individual controls for genetic background, age, environment, and epigenetic effects to allow the detailed analysis and comparison of cell types that are shared between tissues.

Experiments in tumor-bearing mice indicated that breast tumors—including the most malignant triple-negative breast cancers—with high levels of MYO10 responded favorably to immune checkpoint inhibitor therapy, supporting the use of this type of treatment against these tumors.